Page last updated: 2024-11-08

prolyl-lysyl-glycinamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

prolyl-lysyl-glycinamide: protective against puromycin-induced amnesia in mice; RN given refers to (L-Pro-L-Lys)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID171431
CHEMBL ID2371661
SCHEMBL ID11657833
MeSH IDM0093967

Synonyms (9)

Synonym
prolyllysylglycinamide
CHEMBL2371661
pro-lys-gly-amide
prolyl-lysyl-glycinamide
glycinamide, l-prolyl-l-lysyl-
55299-63-3
SCHEMBL11657833
DTXSID80203815
(s)-n-((s)-6-amino-1-((2-amino-2-oxoethyl)amino)-1-oxohexan-2-yl)pyrrolidine-2-carboxamide

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Tremorolytic potency (ED50) was calculated from dose-response curves."( Cholecystokinin octapeptide (CCK-8), ceruletide and analogues of ceruletide: effects on tremors induced by oxotremorine, harmine and ibogaine. A comparison with prolyl-leucylglycine amide (MIF), anti-Parkinsonian drugs and clonazepam.
Zetler, G, 1983
)
0.27
" Analogues 3-6 and 8 exhibited dose-response curves that were bell-shaped in nature with the maximum effect occurring at a concentration of 1 microM."( Synthesis and dopamine receptor modulating activity of lactam conformationally constrained analogues of Pro-Leu-Gly-NH2.
Johnson, RL; Mishra, RK; Sreenivasan, U, 1993
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID118943Ability to reverse electroconvulsive shock-induced amnesia in rodents following 1 ug/kg i.m. administration.1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Modified di- and tripeptides of the C-terminal portion of oxytocin and vasopressin as possible cognition activation agents.
AID191727Ability (% reversal in rats) to reverse electroconvulsive shock-induced amnesia in rodents at a dose of 0.10 (mg/kg) (following intramuscular dosing)1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Modified di- and tripeptides of the C-terminal portion of oxytocin and vasopressin as possible cognition activation agents.
AID118946Ability to reverse electroconvulsive shock-induced amnesia in rodents following 0.1 mg/kg i.m. administration.1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Modified di- and tripeptides of the C-terminal portion of oxytocin and vasopressin as possible cognition activation agents.
AID118944Ability to reverse electroconvulsive shock-induced amnesia in rodents following 0.01 mg/kg i.m. administration.1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Modified di- and tripeptides of the C-terminal portion of oxytocin and vasopressin as possible cognition activation agents.
AID191723Ability (% reversal in rats) to reverse electroconvulsive shock-induced amnesia in rodents at a dose of 0.010 (mg/kg) administered intramuscularly (im)1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Modified di- and tripeptides of the C-terminal portion of oxytocin and vasopressin as possible cognition activation agents.
AID191721Ability (% reversal in rats) to reverse electroconvulsive shock-induced amnesia in rodents at a dose of 0.0010 (mg/kg) (following i.m. administration)1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Modified di- and tripeptides of the C-terminal portion of oxytocin and vasopressin as possible cognition activation agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908 (80.00)18.7374
1990's2 (20.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.74

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.74 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index4.31 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.74)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (9.09%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (90.91%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]